This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Generation of a chemical genetic model for JAK3
Scientific Reports Open Access 12 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 31, 3–4 (2013). https://doi.org/10.1038/nbt0113-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0113-3
This article is cited by
-
Generation of a chemical genetic model for JAK3
Scientific Reports (2021)
-
New partner for Galapagos JAK drug
Nature Biotechnology (2016)
-
Setback for JAK2 inhibitors
Nature Biotechnology (2014)